Praxis Precision Medicines, Inc. (PRAX)
$344.75-$23.10 (-6.28%) Today
Latest PRAX Insider Trades
Jill Desimone - DirectorOpen-market sale
Jill Desimone - DirectorJill Desimone - DirectorJill Desimone - DirectorJill Desimone - DirectorJill Desimone - DirectorJill Desimone - DirectorJill Desimone - DirectorJill Desimone - DirectorPraxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
https://www.praxismedicines.comSEC filings for PRAX on EDGAR
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 12 | 11,600 | $3.61M |
| Grant or award | 16 | 16,152 | |
| Option exercise | 4 | 23,200 | |
| Bona-fide gift | 2 | 23,121 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
28 Form 4 filings on record, the earliest from Nov 15, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
 Marcio Souza - Officer | Gift | Common Stock | 20,521 | $0.00 | - | |
| Marcio Souza - Officer | Gift | Common Stock | 2,600 | $0.00 | - | |
| Jill Desimone - Director | Open-market sale | Common Stock | 2,854 | $311.91 | $890K | |
| Jill Desimone - Director | Open-market sale | Common Stock | 1,004 | $312.83 | $314K | |
| Jill Desimone - Director | Open-market sale | Common Stock | 504 | $313.66 | $158K | |
| Jill Desimone - Director | Open-market sale | Common Stock | 1,279 | $314.90 | $403K | |
| Jill Desimone - Director | Open-market sale | Common Stock | 837 | $315.71 | $264K | |
| Jill Desimone - Director | Option exercise | Stock Option (Right to Buy) | 8,566 | $0.00 | - | |
| Jill Desimone - Director | Option exercise | Stock Option (Right to Buy) | 3,034 | $0.00 | - | |
| Jill Desimone - Director | Option exercise | Common Stock | 8,566 | $44.25 | $379K | |
| Jill Desimone - Director | Option exercise | Common Stock | 3,034 | $147.30 | $447K | |
| Jill Desimone - Director | Open-market sale | Common Stock | 10 | $301.44 | $3K | |
| Jill Desimone - Director | Open-market sale | Common Stock | 120 | $303.13 | $36K | |
| Jill Desimone - Director | Open-market sale | Common Stock | 320 | $305.31 | $98K | |
| Jill Desimone - Director | Open-market sale | Common Stock | 683 | $306.77 | $210K | |
| Jill Desimone - Director | Open-market sale | Common Stock | 1,240 | $308.24 | $382K | |
| Jill Desimone - Director | Open-market sale | Common Stock | 999 | $309.38 | $309K | |
| Jill Desimone - Director | Open-market sale | Common Stock | 1,750 | $310.89 | $544K | |
| Stuart A. Arbuckle - Director | Grant or award | Stock Option (Right to Buy) | 648 | $0.00 | - | |
| Stuart A. Arbuckle - Director | Grant or award | Common Stock | 1,371 | $0.00 | - | |
 Jeffrey Chodakewitz - Director | Grant or award | Common Stock | 1,371 | $0.00 | - | |
| Jeffrey Chodakewitz - Director | Grant or award | Stock Option (Right to Buy) | 648 | $0.00 | - | |
| William D. Young - Director | Grant or award | Common Stock | 1,371 | $0.00 | - | |
| William D. Young - Director | Grant or award | Stock Option (Right to Buy) | 648 | $0.00 | - | |
| Jill Desimone - Director | Grant or award | Stock Option (Right to Buy) | 648 | $0.00 | - | |
| Jill Desimone - Director | Grant or award | Common Stock | 1,371 | $0.00 | - | |
| Merit Ester Cudkowicz - Director | Grant or award | Common Stock | 1,371 | $0.00 | - | |
| Merit Ester Cudkowicz - Director | Grant or award | Stock Option (Right to Buy) | 648 | $0.00 | - | |
| Dean J. Mitchell - Director | Grant or award | Common Stock | 1,371 | $0.00 | - | |
| Dean J. Mitchell - Director | Grant or award | Stock Option (Right to Buy) | 648 | $0.00 | - | |
 Jeffrey B. Kindler - Director | Grant or award | Common Stock | 1,371 | $0.00 | - | |
| Jeffrey B. Kindler - Director | Grant or award | Stock Option (Right to Buy) | 648 | $0.00 | - | |
| Gregory Norden - Director | Grant or award | Stock Option (Right to Buy) | 648 | $0.00 | - | |
| Gregory Norden - Director | Grant or award | Common Stock | 1,371 | $0.00 | - | |
| Lauren Mastrocola - Officer | Grant or award | Common Stock | 127 | $167.94 | $21K | |
| Alex Nemiroff - Officer | Grant or award | Common Stock | 78 | $167.94 | $13K | |
| Timothy Edwin Kelly - Officer | Grant or award | Common Stock | 121 | $167.94 | $20K | |
 Megan Sniecinski - Officer | Grant or award | Common Stock | 89 | $167.94 | $15K | |
| Marcio Souza - Officer | Grant or award | Common Stock | 126 | $167.94 | $21K | |
| Stuart A. Arbuckle - Director | Grant or award | Common Stock | 688 | $0.00 | - | |
| Stuart A. Arbuckle - Director | Grant or award | Common Stock | 478 | $0.00 | - | |
| Stuart A. Arbuckle - Director | Grant or award | Stock Option (Right to Buy) | 224 | $0.00 | - | |
| Jeffrey B. Kindler - Director | Grant or award | Common Stock | 688 | $0.00 | - | |
| Jeffrey B. Kindler - Director | Grant or award | Common Stock | 478 | $0.00 | - | |
| Jeffrey B. Kindler - Director | Grant or award | Stock Option (Right to Buy) | 224 | $0.00 | - | |
| Timothy Edwin Kelly - Officer | Grant or award | Common Stock | 384 | $31.62 | $12K | |
| Lauren Mastrocola - Officer | Open-market sale | Common Stock | 2,145 | $192.71 | $413K | |
| Lauren Mastrocola - Officer | Option exercise | Stock Option (Right to Buy) | 1,047 | $0.00 | - | |
| Lauren Mastrocola - Officer | Option exercise | Stock Option (Right to Buy) | 508 | $0.00 | - | |
| Lauren Mastrocola - Officer | Option exercise | Stock Option (Right to Buy) | 1,557 | $0.00 | - | |
| Lauren Mastrocola - Officer | Option exercise | Stock Option (Right to Buy) | 2,680 | $0.00 | - | |
| Lauren Mastrocola - Officer | Option exercise | Stock Option (Right to Buy) | 2,351 | $0.00 | - | |
| Lauren Mastrocola - Officer | Option exercise | Stock Option (Right to Buy) | 5,250 | $0.00 | - | |
| Lauren Mastrocola - Officer | Option exercise | Common Stock | 1,047 | $49.50 | $52K | |
| Lauren Mastrocola - Officer | Option exercise | Common Stock | 508 | $83.85 | $43K | |
| Lauren Mastrocola - Officer | Option exercise | Common Stock | 1,557 | $133.65 | $208K | |
| Lauren Mastrocola - Officer | Option exercise | Common Stock | 2,680 | $43.37 | $116K | |
| Lauren Mastrocola - Officer | Option exercise | Common Stock | 207 | $44.40 | $9K | |
| Lauren Mastrocola - Officer | Option exercise | Common Stock | 2,351 | $44.40 | $104K | |
| Lauren Mastrocola - Officer | Option exercise | Common Stock | 5,250 | $56.94 | $299K | |
| Lauren Mastrocola - Officer | Option exercise | Stock Option (Right to Buy) | 207 | $0.00 | - | |
| Lauren Mastrocola - Officer | Open-market sale | Common Stock | 11,455 | $191.96 | $2.20M | |
| Alex Nemiroff - Officer | Option exercise | Stock Option (Right to Buy) | 1,714 | $0.00 | - | |
| Alex Nemiroff - Officer | Option exercise | Stock Option (Right to Buy) | 6,230 | $0.00 | - | |
| Alex Nemiroff - Officer | Option exercise | Stock Option (Right to Buy) | 5,652 | $0.00 | - | |
| Alex Nemiroff - Officer | Option exercise | Stock Option (Right to Buy) | 9,100 | $0.00 | - | |
| Alex Nemiroff - Officer | Option exercise | Common Stock | 1,714 | $83.85 | $144K | |
| Alex Nemiroff - Officer | Option exercise | Common Stock | 6,230 | $133.65 | $833K | |
| Alex Nemiroff - Officer | Option exercise | Common Stock | 2,434 | $44.40 | $108K | |
| Alex Nemiroff - Officer | Option exercise | Common Stock | 5,652 | $44.40 | $251K | |
| Alex Nemiroff - Officer | Option exercise | Common Stock | 9,100 | $56.94 | $518K | |
| Alex Nemiroff - Officer | Open-market sale | Common Stock | 9,100 | $194.30 | $1.77M | |
| Alex Nemiroff - Officer | Open-market sale | Common Stock | 1,714 | $190.86 | $327K | |
| Alex Nemiroff - Officer | Open-market sale | Common Stock | 13,339 | $192.53 | $2.57M | |
| Alex Nemiroff - Officer | Open-market sale | Common Stock | 977 | $193.23 | $189K | |
| Alex Nemiroff - Officer | Option exercise | Stock Option (Right to Buy) | 2,434 | $0.00 | - | |
| Adage Capital Management, L.P. - 10% Owner | Open-market sale | Common Stock | 447 | $91.04 | $41K | |
| Adage Capital Management, L.P. - 10% Owner | Open-market sale | Common Stock | 487 | $131.64 | $64K | |
| Adage Capital Management, L.P. - 10% Owner | Open-market sale | Common Stock | 308 | $132.19 | $41K | |
| Adage Capital Management, L.P. - 10% Owner | Open-market sale | Common Stock | 1,363 | $92.03 | $125K | |
| Adage Capital Management, L.P. - 10% Owner | Open-market sale | Common Stock | 559 | $100.11 | $56K | |
| Adage Capital Management, L.P. - 10% Owner | Open-market sale | Common Stock | 27,287 | $101.00 | $2.76M | |
| Adage Capital Management, L.P. - 10% Owner | Open-market sale | Common Stock | 250,000 | $104.31 | $26.08M | |
| Adage Capital Management, L.P. - 10% Owner | Open-market sale | Common Stock | 1,661 | $130.10 | $216K | |
| Adage Capital Management, L.P. - 10% Owner | Open-market sale | Common Stock | 19,198 | $140.00 | $2.69M | |
| Adage Capital Management, L.P. - 10% Owner | Open-market sale | Common Stock, $0.0001 par value per share ("Common Stock") | 12,600 | $90.00 | $1.13M | |
| Dean J. Mitchell - Director | Option exercise | Common Stock | 1,932 | $14.36 | $28K | |
| Dean J. Mitchell - Director | Option exercise | Common Stock | 8,566 | $44.25 | $379K | |
| Dean J. Mitchell - Director | Option exercise | Common Stock | 1,753 | $44.04 | $77K | |
| Dean J. Mitchell - Director | Option exercise | Stock Option (Right to Buy) | 1,932 | $0.00 | - | |
| Dean J. Mitchell - Director | Option exercise | Stock Option (Right to Buy) | 8,566 | $0.00 | - | |
| Dean J. Mitchell - Director | Option exercise | Stock Option (Right to Buy) | 1,753 | $0.00 | - | |
| William D. Young - Director | Grant or award | Stock Option (Right to Buy) | 10,520 | $0.00 | - | |
| Dean J. Mitchell - Director | Grant or award | Stock Option (Right to Buy) | 10,520 | $0.00 | - | |
| Timothy Edwin Kelly - Officer | Grant or award | Common Stock | 205 | $37.40 | $8K | |
| Lauren Mastrocola - Officer | Grant or award | Common Stock | 294 | $37.40 | $11K | |
| Alex Nemiroff - Officer | Option exercise | Common Stock | 7,583 | $56.94 | $432K | |
| Alex Nemiroff - Officer | Open-market sale | Common Stock | 8,239 | $80.20 | $661K | |
| Alex Nemiroff - Officer | Option exercise | Stock Option (Right to Buy) | 7,583 | $0.00 | - | |
| Lauren Mastrocola - Officer | Option exercise | Common Stock | 4,374 | $56.94 | $249K | |
| Lauren Mastrocola - Officer | Open-market sale | Common Stock | 5,188 | $81.78 | $424K | |
| Lauren Mastrocola - Officer | Option exercise | Stock Option (Right to Buy) | 4,374 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR |
Praxis Precision Medicines, Inc. (PRAX) had 10 insider filings in the last 90 days, with the most recent on 2026-07-08. The full record for PRAX runs to 28 Form 4 filings, the earliest from 2024-11-15. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of PRAX were filed in the last 90 days.
12 insider sales of PRAX were filed in the last 90 days, totaling $3.61M.
This page tracks PRAX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add PRAX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
